Cantor Fitzgerald Forecasts NAMS FY2026 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS) – Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for NewAmsterdam Pharma in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the company will post earnings per share of ($2.25) for the year. Cantor Fitzgerald has a “Overweight” rating and a $42.00 price objective on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share.

NAMS has been the subject of several other reports. Scotiabank lifted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Thursday, February 27th. UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Stifel Nicolaus assumed coverage on shares of NewAmsterdam Pharma in a report on Tuesday. They issued a “buy” rating and a $44.00 price objective on the stock. Needham & Company LLC dropped their price objective on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.00.

NewAmsterdam Pharma Stock Up 8.3%

Shares of NASDAQ NAMS opened at $21.84 on Tuesday. The business’s 50 day moving average price is $17.90 and its two-hundred day moving average price is $20.87. The company has a market cap of $2.45 billion, a PE ratio of -11.62 and a beta of -0.03. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). The firm had revenue of $2.98 million for the quarter, compared to the consensus estimate of $1.46 million.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of hedge funds have recently bought and sold shares of NAMS. abrdn plc boosted its holdings in NewAmsterdam Pharma by 38.7% in the 4th quarter. abrdn plc now owns 179,060 shares of the company’s stock valued at $4,602,000 after purchasing an additional 50,000 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $80,000. TimesSquare Capital Management LLC grew its position in NewAmsterdam Pharma by 250.9% during the fourth quarter. TimesSquare Capital Management LLC now owns 895,574 shares of the company’s stock worth $23,016,000 after buying an additional 640,329 shares in the last quarter. Handelsbanken Fonder AB bought a new position in NewAmsterdam Pharma during the 4th quarter worth $4,816,000. Finally, Keybank National Association OH bought a new position in NewAmsterdam Pharma during the 4th quarter worth $257,000. 89.89% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, Director James N. Topper bought 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The stock was bought at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the transaction, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. The trade was a 0.04% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.